Key facts
- It has raised $13.9M; the latest was Grant ($5.9M) in Nov 2025.
- Notable investors include The Grantham Foundation, Wellcome Trust, Neurone, Algebris (UK), Corbites — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Biocentis
- ·The full record, as it builds
Funding rounds
No funding rounds for Biocentis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biocentis
Operator of a genetic control technology designed to target harmful insect species that transmit diseases, destroy crops, and threaten biodiversity. The company offers innovative, precision-driven genetic techniques, enabling agriculture, public health, and environmental sectors to reduce the impact of insect-borne threats, fostering healthier ecosystems and improved crop yields.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 20
- Website
- biocentis.com/
- Ownership
- Privately Held (backing)
Biocentis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biocentis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biocentis in its N-PORT filings yet. We sweep new filings monthly.